[ET Net News Agency, 29 July 2020] WuXi Biologics (Cayman) Inc. (02269) said it is
expected that the profit attributable to equity shareholders of the company for the six
months ended 30 June 2020 will increase more than 58% as compared with the profit
attributable to equity shareholders of the company for the corresponding period of last
year.
Such increase was primarily attributable to (i) immediate and effective implementation
of business continuity plan to minimize the impact of the COVID-19 pandemic on its
business and operations; (ii) more client projects were added into the group's pipeline
expediting the development and manufacturing of potential treatments related to COVID-19
in support of its global clients; (iii) utilization improvement of existing capacities,
which were partially offset by the ramp-up of new sites, and by the increase of
administrative expenses in line with the group's business growth; and (iv) gains from
investments, foreign exchange, tax refund from prior years and other non-operating income
recorded. (RC)
|
|
|
|
|
|
|
|
|
|
Super Quote | Detail Quote | Interactive Chart | Transaction | Related News | Related Securities | Company Information | Dividend Records | Short Sell
02269 WUXI BIO
Nominal 
13.480 +0.740 (+5.808%) Others
29/07/2020 14:57
WuXi Bio (02269) sees 58% increase in interim net
| Remark: | Real time quote last updated: 26/04/2024 18:00 |
| Real-time basic market prices of Hong Kong securities are provided by HKEx; a Designated Website authorized by the HKEx Group to provide the Service |